Personalis Shares Outstanding 2018-2024 | PSNL

Personalis shares outstanding from 2018 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Personalis Annual Shares Outstanding
(Millions of Shares)
2023 48
2022 46
2021 44
2020 34
2019 18
2018 3
2017 3
Personalis Quarterly Shares Outstanding
(Millions of Shares)
2024-06-30 52
2024-03-31 51
2023-12-31 48
2023-09-30 49
2023-06-30 48
2023-03-31 47
2022-12-31 46
2022-09-30 46
2022-06-30 46
2022-03-31 45
2021-12-31 44
2021-09-30 45
2021-06-30 44
2021-03-31 42
2020-12-31 34
2020-09-30 35
2020-06-30 32
2020-03-31 31
2019-12-31 18
2019-09-30 31
2019-06-30 7
2019-03-31 3
2018-12-31
2018-09-30 3
2018-06-30 3
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.270B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00